{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:04:29Z","timestamp":1790899469349,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Genetics and Cytogenetics"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.cancergencyto.2010.07.118","type":"journal-article","created":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T10:25:04Z","timestamp":1292322304000},"page":"222-229","source":"Crossref","is-referenced-by-count":64,"title":["EGFR expression and gene copy number in triple-negative breast carcinoma"],"prefix":"10.1016","volume":"203","author":[{"given":"Berrak","family":"Gumuskaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Alper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Hucumenoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadri","family":"Altundag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Uner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnur","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergencyto.2010.07.118_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib2","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.ejca.2006.08.015","article-title":"Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance","volume":"42","author":"Rakha","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2559.2006.02453.x","article-title":"Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast","volume":"49","author":"Fulford","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.breast.2006.09.003","article-title":"The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies","volume":"16","author":"Siziopikou","year":"2007","journal-title":"Breast"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/modpathol.3800528","article-title":"Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma","volume":"19","author":"Livasy","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib7","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-07-1658","article-title":"Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype","volume":"14","author":"Cheang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib8","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/bcr1827","article-title":"Are triple-negative tumours and basal-like breast cancer synonymous?","volume":"9","author":"Rakha","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib10","first-page":"15","article-title":"Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers","volume":"20","author":"Vokes","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib11","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","article-title":"Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer","volume":"24","author":"Hirsch","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/modpathol.3800438","article-title":"EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations","volume":"18","author":"Bhargava","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.2004","article-title":"EGFR amplification and lack of activating mutations in metaplastic breast carcinomas","volume":"209","author":"Reis-Filho","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/1535-7163.MCT-07-0570","article-title":"Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy","volume":"7","author":"Gilbert","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib15","unstructured":"Gwin K, Lezon-Geyda K, Harris L, Tavassoli FA. Chromosome 7 aneusomy in metaplastic breast carcinomas with chondroid, squamous, and spindle-cell differentiation. Int J Surg Pathol (In press)."},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/1471-2407-8-309","article-title":"Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers","volume":"8","author":"Toyama","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib17","series-title":"World Health Organization classification of tumours","article-title":"Pathology and genetics of the breast and female genital organs","author":"Tavassoli","year":"2003"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib19","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib20","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib21","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib22","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2005.05.4692","article-title":"Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations","volume":"24","author":"Inoue","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.lungcan.2007.01.025","article-title":"Phase II prospective study of the efficacy of gefitinib for the treatment of stage III\/IV non\u2013small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy","volume":"56","author":"Sunaga","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib24","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/sj.bjc.6603466","article-title":"Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid\u2013locked nucleic acid PCR clamp","volume":"95","author":"Sutani","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2353\/jmoldx.2008.070178","article-title":"EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression","volume":"10","author":"Li","year":"2008","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib26","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/annonc\/mdm003","article-title":"Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib","volume":"18","author":"Hirsch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib27","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2007.14.0111","article-title":"Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy","volume":"26","author":"Hirsch","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.5858\/133.3.470","article-title":"Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib","volume":"133","author":"Zakowski","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib29","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1073\/pnas.89.10.4309","article-title":"Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and\/or C-terminal tails","volume":"89","author":"Ekstrand","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cancergencyto.2010.07.118_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.pai.0000155794.64525.11","article-title":"Selecting antibodies to detect HER-2 overexpression by immunohistochemistry in invasive mammary carcinomas","volume":"14","author":"Gouvea","year":"2006","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["Cancer Genetics and Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460810004085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460810004085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:12:23Z","timestamp":1636974743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165460810004085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0165460810004085"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2010.07.118","relation":{},"ISSN":["0165-4608"],"issn-type":[{"value":"0165-4608","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}